Professor Mike Page and Dr. Karl Hemming and colleagues at the University of Huddersfield are the first to develop a drug that mitigates and eliminates the detrimental effects of binge drinking on the human brain. The drug is designed to be taken before any alcohol has been consumed.
Ethane-beta-sultam enters the human body without being broken down in any way. The drug acts to limit the production of glial cells that are produced by the human brain in response to the consumption of large quantities of alcohol in a short period of time. Excessive glial cell production produces inflammation that can kill brain cells.
The drug is designed to be taken before or during a heavy drinking episode. The results in rat studies indicate that excessive glial cell production was eliminated by taking the drug. The drug offers the potential to protect people from the detrimental problems associated with binge drinking.
The approach can be assessed by Dr. Page’s consideration that ““But if you accept that alcohol abuse is going to continue, then it might be sensible for society to try and treat it in some way.” A marvelously practical approach that addresses human behavior as it exists. One could consider how much money the various governments in the United States could save if they were to dare to be this practical and realistic. The idea is much more realistic that “Just Say No”.
